Patients who live with rare and serious medical conditions often face barriers to getting the care they need. To help patients advocate for themselves, CSL Behring started the Local Empowerment for Advocacy Development (LEAD) grant program. It offers grants of up to $10,000 to patient organizations in the United States – and €10,000 grants to patient groups in Europe – to address issues that affect their communities.
Applications for the U.S. grants are due by the end of October. Learn more about how to apply.
"One of the key things that patient organizations can do is advocate on behalf their communities,” said Roy Pura, CSL Behring’s Associate Director of State Government Affairs, Central U.S. “There is a need to do that, but often they lack the resources despite the walks that they have or their other fundraising endeavors. They need additional resources to help support advocacy efforts, and this is one area that CSL can have an impact.”
Since 2008, LEAD grants have provided over $1.2 million to patient organizations to support local- and state-level advocacy efforts.
CSL Behring, a business unit of CSL, develops and manufactures medicines for people who have rare and serious diseases, such as bleeding disorders, primary immunodeficiencies, chronic inflammatory demyelinating polyneuropathy (CIDP), hereditary angioedema (HAE) and Alpha 1 Antitrypsin Deficiency.
For additional information about the program or any questions, please contact Advocacy@cslbehring.com.
